Rectify

Biotech · Private

Therapeutic approach to restore ABC transporter function in genetic disease patients

rectifypharma.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
1
1 granted · 0 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1811Sapience Therapeutics Inc.—$8.3M
1812Marius Pharmaceuticals, LLC—$5.6M
1813MDI Therapeutics Investors, LLC——
1814Rectify——
1815Phylo——
1816Pupil Bio, Inc.—$500K
1817Hapten Sciences, Inc.—$2.7M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 1

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.